Literature DB >> 27163851

In vitro metabolism of phenytoin in 36 CYP2C9 variants found in the Chinese population.

Lian-Guo Chen1, Zhe Wang2, Yuan Zhu1, Jian-Hua Xiong1, Li-Rong Sun1, Da-Peng Dai3, Jian-Ping Cai4, Guo-Xin Hu5.   

Abstract

Cytochrome P450 2C9 (CYP2C9) is an important member of the cytochrome P450 enzyme superfamily, with 57 CYP2C9 allelic variants being previously reported. Recently, we identified 22 novel alleles (*36 -*56 and N418T) in the Han Chinese population. This study aims to assess the catalytic activities of wild-type (CYP2C9*1) and 36 CYP2C9 allelic variants found in the Chinese population toward phenytoin (PHT) in vitro. Insect microsomes expressing CYP2C9*1 and 36 CYP2C9 variants were incubated with 1-200 μM phenytoin for 30 min at 37 °C. Then, these products were extracted and the signal detection was performed by HPLC-MS/MS. The intrinsic clearance (Vmax/Km) values of all variants, with the exception of CYP2C9*2, CYP2C9*11, CYP2C9*23, CYP2C9*29, CYP2C9*34, CYP2C9*38, CYP2C9*44, CYP2C9*46 and CYP2C9*48, were significantly different from CYP2C9*1. CYP2C9*27, *40, *41, *47, *49, *51, *53, *54, *56 and N418T variant exhibited markedly larger values than CYP2C9*1 (>152.8%), whereas 17 variants exhibited smaller values (from 48.6% to 99.9%) due to larger Km and/or smaller Vmax values than CYP2C9*1. The findings suggest that more attention should be paid on subjects carrying these infrequent CYP2C9 alleles when administering phenytoin in clinic.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Allelic variant; CYP2C9; Catalytic activity; Chinese population; In vitro; Phenytoin

Mesh:

Substances:

Year:  2016        PMID: 27163851     DOI: 10.1016/j.cbi.2016.04.040

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  4 in total

1.  Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People.

Authors:  Matthew G McDonald; Lindsay M Henderson; Sutapa Ray; Catherine K Yeung; Amanda L Johnson; John P Kowalski; Helmut Hanenberg; Constanze Wiek; Kenneth E Thummel; Allan E Rettie
Journal:  J Pharmacol Exp Ther       Date:  2020-05-18       Impact factor: 4.030

Review 2.  Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications.

Authors:  Lauren A Marcath; Amy L Pasternak; Daniel L Hertz
Journal:  Pharmacogenomics J       Date:  2019-10-15       Impact factor: 3.550

3.  The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.

Authors:  Maor Wanounou; Chanan Shaul; Zahi Abu Ghosh; Shoshana Alamia; Yoseph Caraco
Journal:  Clin Pharmacol Ther       Date:  2022-05-05       Impact factor: 6.903

4.  Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling.

Authors:  Heajin Jun; Yan Rong; Catharina Yih; Jordan Ho; Wendy Cheng; Tony K L Kiang
Journal:  Drugs R D       Date:  2020-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.